Patent ID: 9702010
Date: 2017-07-11
CPC Classifications: A61K,A61P,C07K,C12Q

Claim:
1. A method of determining the sensitivity of a malignancy in a patient to Clostridium perfringens enterotoxin (CPE) therapy and treating said malignancy wherein said malignancy is recurrent ovarian serous papillary carcinoma, recurrent ovarian clear cell carcinoma or recurrent uterine serous papillary carcinoma and wherein said recurrent malignancy includes chemotherapy-resistant malignant cells, comprising detecting the presence of claudin-3 and/or claudin-4 in a sample portion of said malignancy from said patient; determining that the patient has a significantly higher expression level of claudin-3 and/or claudin-4 in said chemotherapy-resistant malignant cells compared to chemotherapy naïve malignant cells, wherein a significantly higher expression level of claudin-3 and/or claudin-4 in said chemotherapy-resistant malignant cells compared to said chemotherapy naive malignant cells is evidence that the malignancy is sensitive to CPE therapy; and treating said patient for said malignancy by administering to said patient a therapeutically effective amount of wherein the CPE is native CPE (SEQ ID NO:1) or a variant thereof comprising a sequence at least 90% identical to residues 45-319 of SEQ ID NO:1; wherein the CPE or a pharmaceutically acceptable salt thereof is administered intravenously or intraperitoneally and wherein the CPE preferably binds to chemotherapy-resistant cancerous cells over chemotherapy-sensitive cancer cells.